Pharmaceutical Research最新文献_第4页

Hispidulin Isolated from the Leaves of Clerodendrum inerme (L.) Gaertn Suppresses Trigeminovascular System Activation in a Rat Model Mimicking Migraine. 从毛竹叶中分离得到的Hispidulin在模拟偏头痛的大鼠模型中，Gaertn抑制三叉神经血管系统的激活。

IF 3.5 3区医学

Pharmaceutical Research Pub Date : 2025-06-01 Epub Date: 2025-05-09 DOI: 10.1007/s11095-025-03864-w

Pi-Chuan Fan, Ming Tatt Lee, Tzu-Hsuan Lai, Wei-Jan Huang, Lih-Chu Chiou

{"title":"Hispidulin Isolated from the Leaves of Clerodendrum inerme (L.) Gaertn Suppresses Trigeminovascular System Activation in a Rat Model Mimicking Migraine.","authors":"Pi-Chuan Fan, Ming Tatt Lee, Tzu-Hsuan Lai, Wei-Jan Huang, Lih-Chu Chiou","doi":"10.1007/s11095-025-03864-w","DOIUrl":"10.1007/s11095-025-03864-w","url":null,"abstract":"Background: Hispidulin (6-methoxy-4',5,7-trihydroxyflavone) is a flavonoid commonly found in various plant products, including the leaves of Clerodendrum inerme (L.) Gaertn (CI). While there's an abundance of literature describing the therapeutic effect of hispidulin and CI in oncological, immunological, and dermatological models, their effect on neuropsychiatric disorders is also of research interest.Objective: The previous reports on the neuroprotective and GABAA receptor positive modulatory effect of hispidulin may render it as a possible novel candidate as an antimigraine agent.Methods: In the present study, we employed the intracisternal instillation of capsaicin in anesthetized rats to induce the activation of trigeminovascular system (TGVS), which mimics the histopathological hallmarks of migraine that include increased neuronal activation in the trigeminal cervical complex (TCC), calcitonin gene-related peptide (CGRP) immunoreactivity in the trigeminal ganglia (TG) and CGRP depletion in the dura mater.Results: Administration of hispidulin (4, 10, and 50 mg/kg, i.p.) significantly reduced all three TGVS activation parameters induced by i.c. capsaicin. However, pre-treatment of a selective antagonist for α6 subunit-containing GABAA receptor, furosemide (20 mg/kg, i.p.), did not significantly reverse the antimigraine effect of hispidulin.Conclusion: To the best of our knowledge, this is the first report on hispidulin's suppressive effect on preclinical model of migraine. Further studies are required to explore the mechanism(s) of the antimigraine effect of hispidulin. However, these findings could potentially guide future clinical studies of hispidulin, with the aim of improving human health.","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"1035-1045"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decrease in In Vivo Efflux Transport via P-glycoprotein at the Rat Inner Blood-Retinal Barrier by Peripheral Administration of Lipopolysaccharide. 外周给药降低p -糖蛋白在大鼠血液-视网膜内屏障的体内外排转运。

IF 3.5 3区医学

Pharmaceutical Research Pub Date : 2025-06-01 Epub Date: 2025-06-03 DOI: 10.1007/s11095-025-03872-w

Kiyotaka Daikohara, Shin-Ichi Akanuma, Miyu Kawanishi, Yuma Tega, Ken-Ichi Hosoya

{"title":"Decrease in In Vivo Efflux Transport via P-glycoprotein at the Rat Inner Blood-Retinal Barrier by Peripheral Administration of Lipopolysaccharide.","authors":"Kiyotaka Daikohara, Shin-Ichi Akanuma, Miyu Kawanishi, Yuma Tega, Ken-Ichi Hosoya","doi":"10.1007/s11095-025-03872-w","DOIUrl":"10.1007/s11095-025-03872-w","url":null,"abstract":"Purpose: This study aimed to determine in vivo alterations in the rat retinal distribution of a substrate for P-glycoprotein (P-gp), which restricts drug transport to the retina at the inner blood-retinal barrier (BRB), by peripheral administration of lipopolysaccharide (LPS), an inflammatory agent.Methods: Using retinal capillaries isolated from rats 24 h after peripheral 5 mg/kg LPS administration, transport analyses with a fluorescent substrate of P-gp were performed. In vivo retinal distribution of [3H]digoxin, a P-gp substrate, in the LPS-administered rats was evaluated after intravenous or intracarotid artery injection. The mRNA and protein expression levels of P-gp in the retinal capillaries were evaluated.Results: P-gp-mediated luminal transport of the fluorescent substrate was significantly attenuated in retinal capillaries of the LPS-administered rats. Moreover, in vivo retinal [3H]digoxin distribution in LPS-injected rats was significantly greater than that in saline-injected rats. Since the retinal distribution of [3H]D-mannitol, a paracellular transport marker, was not significantly altered in LPS-treated rats, it is suggested that in vivo elevation of retinal [3H]digoxin distribution is caused by P-gp downregulation at the inner BRB, but not a change in paracellular transport in the barrier. In retinal capillaries isolated from LPS-administered rats, expression analyses of P-gp mRNAs and protein indicated a reduction in its expression on the luminal membrane of the inner BRB.Conclusion: Our study demonstrated that in vivo retinal distribution of P-gp substrates was elevated in LPS-administered rats via a decrease in the function and expression of P-gp at the inner BRB.","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"907-915"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liposomal Vardenafil and Linagliptin Combined with Irinotecan for Synergistic Colorectal Cancer Therapy. 伐地那非、利格列汀联合伊立替康脂质体协同治疗结直肠癌。

IF 3.5 3区医学

Pharmaceutical Research Pub Date : 2025-06-01 Epub Date: 2025-06-05 DOI: 10.1007/s11095-025-03876-6

Xian Zhao, Ruijie Xu, Yuanyuan Zhai, Yi Wang, Yuxin Zhang, Yuan Tian, Fengguo Xu, Pei Zhang

{"title":"Liposomal Vardenafil and Linagliptin Combined with Irinotecan for Synergistic Colorectal Cancer Therapy.","authors":"Xian Zhao, Ruijie Xu, Yuanyuan Zhai, Yi Wang, Yuxin Zhang, Yuan Tian, Fengguo Xu, Pei Zhang","doi":"10.1007/s11095-025-03876-6","DOIUrl":"10.1007/s11095-025-03876-6","url":null,"abstract":"Background: Irinotecan (CPT-11) is a standard first-line chemotherapy treatment for colorectal cancer (CRC). However, its clinical application is often comprised by gastrointestinal toxicity and limited therapeutic efficacy. Our previous study has revealed that the combination of Vardenafil (Vard) and Linagliptin (Linag) significantly alleviated CPT-11-induced intestinal toxicity in both in vitro and in vivo models. It remains unclear whether this combination can synergistically enhance the anticancer activity of CPT-11.Methods: The in vitro synergism of Vard, Linag, and CPT-11 was assessed using cell viability assays on CRC cell lines, including HCT116, SW620, and HT29. An in vivo xenograft mouse model was established to evaluate the drug efficacy of both the original and liposomal forms of Vard and Linag combined with CPT-11. Additionally, untargeted metabolomics was utilized to explore the potential mechanisms underlying the observed synergistic effects.Results: In vitro, the combination of Vard and Linag synergistically enhanced the anticancer activity of CPT-11 in CRC cell lines. In vivo, liposomal formulations of Vard and Linag tended to accumulate at the tumor site, improving drug targeting and synergistically enhancing the anticancer efficacy of CPT-11. Untargeted metabolomics analysis revealed that this synergistic effect was probably mediated through the regulation of lysophospholipid metabolism.Conclusion: Liposomal Vard and Linag combined with CPT-11 demonstrated a synergistic anti-CRC effect, offering valuable insights into novel combination therapies in CRC treatment.","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"935-945"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing Pharmaceutical Security: Noninvasive Detection of Falsified Vaccines and Drugs Using wNMR. 推进药物安全：使用wNMR无创检测伪造疫苗和药物。

IF 3.5 3区医学

Pharmaceutical Research Pub Date : 2025-06-01 Epub Date: 2025-06-13 DOI: 10.1007/s11095-025-03880-w

Marc B Taraban, Katharine T Briggs, Pratima Karki, Leonid Grunin, Y Bruce Yu

{"title":"Advancing Pharmaceutical Security: Noninvasive Detection of Falsified Vaccines and Drugs Using wNMR.","authors":"Marc B Taraban, Katharine T Briggs, Pratima Karki, Leonid Grunin, Y Bruce Yu","doi":"10.1007/s11095-025-03880-w","DOIUrl":"10.1007/s11095-025-03880-w","url":null,"abstract":"Objective: To develop and apply noninvasive analytical technologies to detect falsified vaccines and drugs.Methods: Univariate and multivariate methods, based on the water nuclear magnetic resonance (wNMR) technology, was explored as a tool for noninvasive detection of simple and sophisticated falsified vaccines, biotherapeutics and anesthetics. All wNMR measurements were done noninvasively on sealed vials, prefilled syringes, and injection pens. Saline USP served as a simple falsified drug product while highly similar vaccines and drugs (brand vs. generics/biosimilars) served as each other's sophisticated falsified drug products for technology development and testing.Results: Simple falsified drug products, represented by USP saline, can be differentiated from authentic vaccines and drugs by univariate wNMR. Sophisticated falsified drug products, represented by highly similar products, can be differentiated from authentic ones by univariate wNMR in some cases and by multivariate wNMR in all cases, attesting to the high discriminating power of wNMR in product authentication. The multivariate methods generate 2D and 3D data arrays that may serve as fingerprints of vaccines and drugs.Conclusions: A suite of noninvasive analytical methods, based on the wNMR technology, have been developed to detect falsified vaccines and drugs. wNMR analyzes vaccines and drugs in their primary containers without opening and uses benchtop instruments with no wet lab operations and no reagents. wNMR detection of falsified drug products may be implemented in low-resource settings for enhanced pharmaceutical security and preventive pharmacovigilance.","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"987-1001"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144294777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Leveraging Model Master Files for Long-Acting Injectables. 更正：利用模型主文件进行长效注入。

IF 3.5 3区医学

Pharmaceutical Research Pub Date : 2025-05-01 DOI: 10.1007/s11095-025-03832-4

Yuqing Gong, Robert Hopefl, Tonglei Li, Andrew C Hooker, Daniela Amaral Silva, Khondoker Alam, Murray Ducharme, Rebecca Moody, Pratik Saha, Andrew Babiskin

引用次数: 0

Industry Perspectives on Implementation of Model Master File (MMF) Framework for Generics and Innovator Drugs: Opportunities, Challenges and Future Outlook. 仿制药和创新药模型主文件（MMF）框架实施的行业展望：机遇、挑战和未来展望。

IF 3.5 3区医学

Pharmaceutical Research Pub Date : 2025-05-01 Epub Date: 2025-03-12 DOI: 10.1007/s11095-025-03844-0

Sivacharan Kollipara, Markus Friden, Tycho Heimbach, Pratik Saha, Jan De Backer, Tausif Ahmed, Timothy Nicholas

{"title":"Industry Perspectives on Implementation of Model Master File (MMF) Framework for Generics and Innovator Drugs: Opportunities, Challenges and Future Outlook.","authors":"Sivacharan Kollipara, Markus Friden, Tycho Heimbach, Pratik Saha, Jan De Backer, Tausif Ahmed, Timothy Nicholas","doi":"10.1007/s11095-025-03844-0","DOIUrl":"10.1007/s11095-025-03844-0","url":null,"abstract":"Modeling and simulation (M&S) based approaches have proven significant utility in both new drug and generic product development. Considering the plethora of applications of such novel approaches, the concept of model master file (MMF) has been introduced recently to streamline the regulatory submission process as well as to facilitate the use of M&S approaches. The MMF has potential to reduce the applicant's efforts in preparing and submitting modeling-based applications and can result in reduced review timelines. Approved MMF's are considered as reusable, sharable, portable and generalizable and thus can be used by the same applicant in multiple submissions or by multiple applicants. To further increase the understanding of the MMF framework and to understand potential applications, and limitations, the USFDA and the Center for Research on Complex Generics (CRCG, https://www.complexgenerics.org ) co-hosted a hybrid public workshop titled \"Considerations and Potential Regulatory Applications for a Model Master File\". This article summarizes the industry perspectives of MMF implementation from both new drug and generic product development perspectives. With the help of diverse case studies, an effort was made in the manuscript to discuss potential challenges, opportunities and benefits. The objective of this article is to portray industry thinking on the MMF concept and the use and implementation of the concept during drug discovery and development. The views presented in this manuscript are of industry participants present at the workshop and not the industry at large.","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"785-794"},"PeriodicalIF":3.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143616762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leveraging Model Master Files from a Technology Company Perspective: Facilitating Quantitative Medicine in Regulatory Frameworks. 从技术公司的角度利用模型主文件：促进监管框架下的定量医学。

IF 3.5 3区医学

Pharmaceutical Research Pub Date : 2025-05-01 Epub Date: 2025-02-26 DOI: 10.1007/s11095-025-03833-3

Jan De Backer, James Clarke, Hosein Sadafi, William Ganley, Jessica Spires

{"title":"Leveraging Model Master Files from a Technology Company Perspective: Facilitating Quantitative Medicine in Regulatory Frameworks.","authors":"Jan De Backer, James Clarke, Hosein Sadafi, William Ganley, Jessica Spires","doi":"10.1007/s11095-025-03833-3","DOIUrl":"10.1007/s11095-025-03833-3","url":null,"abstract":"Model Master Files (MMFs) offer a much needed approach to integrating computational modelling into drug development and regulatory frameworks, supporting the growth of quantitative medicine. By acting as confidential repositories for validated models, MMFs enable streamlined submissions, model reuse, and context-specific reviews while safeguarding intellectual property. For technology companies (such as software providers), MMFs provide a structured pathway to engage with the FDA, align innovations with regulatory standards, and expand the use of models across diverse applications. A challenge with the current framework is the need to provide the same validation and verification information to multiple drug companies each time the submit an application. With an MMF in place, drug companies can refer to this same document which the technology provider can add to over time. However, challenges persist, including limited direct interaction with the FDA outside (A)NDA submissions and the need for consistent model validation and version management. Addressing these issues through enhanced collaboration and clear guidelines will maximize the potential of MMFs, fostering broader adoption of modelling and simulation in drug development and advancing personalized medicine.","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"795-803"},"PeriodicalIF":3.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Paving the Path for Increased Technological Innovation, Strategic Decision Making and Regulatory Acceptance of Modeling and Simulation Approaches. 为增加技术创新，战略决策和监管接受建模和仿真方法铺平道路。

IF 3.5 3区医学

Pharmaceutical Research Pub Date : 2025-05-01 DOI: 10.1007/s11095-025-03868-6

Lanyan Fang, Eleftheria Tsakalozou, James E Polli

引用次数: 0

Using Model Master Files to Support Oral Drug Product Development and Regulatory Submissions. 使用模型主文件支持口服药物产品开发和监管提交。

IF 3.5 3区医学

Pharmaceutical Research Pub Date : 2025-05-01 Epub Date: 2025-05-29 DOI: 10.1007/s11095-025-03865-9

Yi-Hsien Cheng, Arindom Pal, Rebecca Moody, Tycho Heimbach, Viera Lukacova, Nikunjkumar Patel, Gregory Rullo, Yunming Xu, Tausif Ahmed, Essam Kerwash, Lanyan Fang, Fang Wu

{"title":"Using Model Master Files to Support Oral Drug Product Development and Regulatory Submissions.","authors":"Yi-Hsien Cheng, Arindom Pal, Rebecca Moody, Tycho Heimbach, Viera Lukacova, Nikunjkumar Patel, Gregory Rullo, Yunming Xu, Tausif Ahmed, Essam Kerwash, Lanyan Fang, Fang Wu","doi":"10.1007/s11095-025-03865-9","DOIUrl":"10.1007/s11095-025-03865-9","url":null,"abstract":"This report summarizes the proceedings of Session 2 of the two-day public workshop titled \"Considerations and Potential Regulatory Applications for a Model Master File\" hosted by the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) on May 2-3, 2024. The workshop aimed to discuss the frameworks and practical considerations for developing a model master file (MMF) and its applications to support drug product development and streamline regulatory review processes. This report provides a comprehensive and insightful overview of the second session of the workshop titled \"MMF Applications for Oral Dosage Forms\". The presentations, which included several case studies, covered potential frameworks and context of use (COU) of MMFs for oral drug products, practical considerations during model development, validation, and regulatory submission processes, as well as scientific justification for modification on approved MMFs. Additionally, the discussion highlighted the crucial role of global harmonization of MMFs, which can benefit both industry and regulatory authorities by making modeling more resource- and time-efficient while meeting high regulatory standards, ultimately reducing delays in drug development and accelerating the availability of new medicines. MMFs for oral dosage forms are especially advantageous due to the wealth of global resources from various organizations and the opportunity to extend these capabilities to complex generics. Lastly, the session also discussed the potential for using technology to track the lifecycle of accepted MMFs, enabling adaptations and ensuring transparency in their downstream reuse.","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"753-763"},"PeriodicalIF":3.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Considerations for Regulatory Reusability of Dynamic Tools in the New Drug Development. 新药开发中动态工具监管可重用性的考虑。

IF 3.5 3区医学

Pharmaceutical Research Pub Date : 2025-05-01 Epub Date: 2025-03-04 DOI: 10.1007/s11095-025-03831-5

Jiang Liu, Yuching Yang, Joga Gobburu, Cynthia J Musante, Martin Klein, Liang Zhao, Rajanikanth Madabushi, Hao Zhu

{"title":"Considerations for Regulatory Reusability of Dynamic Tools in the New Drug Development.","authors":"Jiang Liu, Yuching Yang, Joga Gobburu, Cynthia J Musante, Martin Klein, Liang Zhao, Rajanikanth Madabushi, Hao Zhu","doi":"10.1007/s11095-025-03831-5","DOIUrl":"10.1007/s11095-025-03831-5","url":null,"abstract":"Model-informed drug development (MIDD) approaches have become indispensable for new drug development and to address regulatory challenges. Dynamic tools, such as population pharmacokinetics (popPK), physiologically-based pharmacokinetics (PBPK), and quantitative systems pharmacology (QSP) models, are routinely employed to enhance the efficiency of drug development. Recently, the Fit-for-Purpose (FFP) initiative and the Model Master File (MMF) framework have emerged to support model reusability and sharing in regulatory settings. In this manuscript we share key insights from the Session \"Pathways for Regulatory Acceptance of Dynamic Tools in the New Drug Space\" of Workshop \"Considerations and Potential Regulatory Applications for a Model Master File\", hosted by the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) and discuss the considerations for regulatory acceptance of dynamic modeling tools. Presentations at the workshop explored current practices in PBPK model evaluation, the potential for popPK models in bioequivalence (BE) assessments, and the implications of reusing models. Challenges such as context-specific validation, version control, and the impact of scientific and technological advancements on model reuse were emphasized. The workshop underscored the importance of clear regulatory pathways and structured frameworks for the consistent application of reusable models. The MMF's potential to streamline reviews and reduce redundancies was noted, although operational details require further elaboration. Continued collaboration among stakeholders is essential to refine model-sharing practices, enhance model validation processes, and promote transparency, ensuring that MIDD approaches remain robust and adaptable to evolving regulatory needs.","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"765-771"},"PeriodicalIF":3.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0